Established in Hong Kong to facilitate an IPO in China, GCHK is the parent company of GC China and plays a pivotal role in financing its subsidiary.
GC China, established as part of GC Pharma’ global expansion strategy, produces plasma-derived products. Since passing the Chinese National Health and Family Planning Commission of the People’s Republic of China’s on-site inspection and obtaining a safety certificate in 1998, the company has gone on to become the first in Anhui Province to satisfy the Chinese government’s Good Manufacturing Practice (GMP) standard with its advanced systems and facilities. The company currently procures the blood plasma it needs from seven depositories in total, including six in Anhui and one in Hunan.
A subsidiary of GC China, GC Chinapharm is a pharmaceutical wholesaler established by GC Pharmaj for the distribution of pharmaceutical products in China. The company is expected to buttress GC China’s continued growth through effective marketing and distribution of GC China products to local clients. Gelinker currently operates six distributorships across the nation, including the main one at Shanghai.
The holding company of GCBT, GCNA provides efficient financing for GCBT.
Established in Montreal as a forward base for launching into the plasma-derived product market in North America, GCBT is currently building its plant. The products it will produce will mainly target the advanced North American markets in the United States and Canada after the authorities’ approval.
Boasting quarantine and containment systems of the highest quality, Invacfarm produces and supplies fertile eggs from its state-of-the-art poultry farm and hatcheries, which meet the standard for vaccine production. Invacfarm provides a steady supply of quality eggs to GC Pharma, performing an indispensable role in the company’s development and production of flu vaccines.